U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07794254) titled 'A Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 2 Diabetes Mellitus' on Aug. 26.

Brief Summary: This Phase I/II clinical trial is a multi-center, single-arm, open-label study aimed at evaluating the safety and efficacy of RGB-5088 islet cell infusion in patients with Type 2 Diabetes Mellitus.

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Diabete Mellitus Diabete Type 2

Intervention: BIOLOGICAL: RGB-5088

Transplantation under the anterior rectus sheath

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hangzhou Reprogenix Bioscience, Inc

Disclaimer: Curated by HT Syndic...